MedTrace Logo

The Confirmatory Olmesartan Plaque Regression Study

NCT01132768 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2018-12-24

No results posted yet for this study

Summary

Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.

Conditions

  • Essential Hypertension
  • Carotid Plaque

Interventions

DRUG

Atenolol

Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily

DRUG

olmesartan medoxomil

Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily

Sponsors & Collaborators

  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    lead INDUSTRY

Principal Investigators

  • Klaus O Stumpe, MD · Centre of Preventative Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01132768 on ClinicalTrials.gov